Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Nationwide Children's Hospital· Source
Not yet recruiting
Post-intervention dual antiplatelet therapy for mild stroke
2026-525681-22-00· Phase 3· Technische Universitaet Dresden· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181· Phase 2· Boehringer Ingelheim· Source
Recruiting
Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial
2024-516544-26-00· Phase 2· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281· Phase 3· AstraZeneca· Source
Recruiting
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
NCT07176312· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· Phase 3· Amgen Inc.· Source
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426· argenx· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· Phase 3· Gilead Sciences· Source
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514· Phase 3· Summit Therapeutics· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
NCT07803848· Phase 2· AIO-Studien-gGmbH· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155· Phase 2· argenx· Source
Enrolling by invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742· Phase 3· Viatris Innovation GmbH· Source
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314· Phase 3· Immunocore Ltd· Source
Active, not recruiting
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803· Phase 3· AstraZeneca· Source
Active, not recruiting
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576· Phase 3· Viatris Innovation GmbH· Source
Recruiting
Venetoclax in combination with Ibrutinib and Rituximab or conventional
chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients
with Mantle Cell Lymphoma.
2022-501808-96-00· Phase 2· Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR· Source
Active, not recruiting
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266· Phase 3· AstraZeneca· Source
Recruiting
DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device
NCT05543447· Acandis GmbH· Source
Active, not recruiting
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
NCT05452213· Phase 4· Institut Für Frauengesundheit GmbH· Source
Recruiting
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05009082· Phase 3· AGO Study Group· Source
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697· Phase 1/2· ModernaTX, Inc.· Source
Recruiting
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00· Phase 3· GPOH gGmbH· Source
Recruiting
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
NCT05007132· Phase 2· Dominik Paul Modest· Source
Recruiting
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· Phase 3· The University Of Birmingham· Source
Active, not recruiting
The SELUTION DeNovo Study
NCT04859985· M.A. Med Alliance S.A.· Source
Active, not recruiting
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414· Phase 3· Celgene· Source
Active, not recruiting
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
NCT04602533· Phase 2· Michael Hopp· Source
Active, not recruiting
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
First in Men Study: BIOMAG-I
NCT04157153· Biotronik AG· Source
Recruiting
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
2022-501454-11-00· Phase 3· GPOH gGmbH· Source
Active, not recruiting
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
NCT03897127· Phase 3· University of Ulm· Source
Active, not recruiting
Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours
2023-507582-25-00· Phase 3· Rheinische Friedrich-Wilhelms-Universitaet Bonn· Source
Active, not recruiting
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
NCT03366545· Biotronik SE & Co. KG· Source
Active, not recruiting
Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
NCT03333187· Phase 2· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
NCT02265770· Phase 2/3· Centre Leon Berard· Source
Recruiting
International HIT-MED Registry (I-HIT-MED)
NCT02417324· Universitätsklinikum Hamburg-Eppendorf· Source
Active, not recruiting
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
NCT01594723· Phase 2· Eli Lilly and Company· Source
Recruiting
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
NCT01252485· University of Ulm· Source
Recruiting
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
NCT02872987· Goethe University· Source